PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29207150-10	2018	Western blotting results indicated that sorafenib concurrently inhibited the activities of the MAPK and AKT/mTOR pathways in thyroid cancer.	Sorafenib	40-49	AKT serine/threonine kinase 1	Homo sapiens	104-107	
29207150-11	2018	Autophagy was activated by sorafenib in thyroid cancer, both in vitro and in vivo, which was at least in part due to suppression of the AKT/mTOR pathway.	Sorafenib	27-36	AKT serine/threonine kinase 1	Homo sapiens	136-139